In our research team, we are mainly interested by "molecular programming" with the aim to explore or manipulate complex biological systems such as living cells or organisms. In other words, we design molecules that have built into their structure a chemical program enabling them to perform specific tasks autonomously within biological environments. Recently, we developed various molecular devices programmed for the selective delivery of anticancer drugs. These functional systems include programming components like self-immolative linkers, chemical amplifiers, self-opening macrocycles, etc... that pilot the process of drug release in a stringently controlled fashion.
Chem sci 2017
Highlighted on the website of the university of Poitiers here,
read our new article in Chemical Science : Targeting the Tumour Microenvironment with Enzyme-Responsive Drug Delivery System for Efficient Therapy of Breast and Pancreatic Cancers,
B. Renoux, F. Raes, T. Legigan, E. Peraudeau, B. Eddhif, P. Poinot, I. Tranoy-Opalinski, J. Alsarraf, O. Koniev, S. Kolodych, S. Lerondel, A. Le Pape, J. Clarhaut and S. Papot, Chem. Sci., 2017
Sunshine team
Our transdisciplinary team ready for summer work under the sunshine.
Eur. J. Med. Chem. 2017
Read our new article in Chemical Science : In situ targeted activation of an anticancer agent using ultrasound-triggered release of composite droplets,
PoitiersMag Mars 2017
This month find a article about the creation of the new Pr. S. Papot’s startup : ProTarget in an article in PoitiersMag
Last Evening, Pr. PAPOT won the Price « Top émergence » at the « Top entreprises de la Vienne » for his new startup « Pro Target ».
All details in the Nouvelle République, Centre Presse or here.
Peptide Science Cover
Read our new article in Peptide Science: Diminished oligomerization in the synthesis of new anti-angiogenic cyclic peptide using solution instead of solid-phase cyclization.
Comptes rendus de chimie frontpage
Read our new article in the special issue « Emerging Chemistry in France » of Comptes Rendus Chimie
« Rotaxane-based architectures for biological applications »
Therapeutic impact
Now, the time has come to push to the clinic our most promising drug delivery system for cancer chemotherapy. To this end, we need to carry out the full preclinical study. The cost of this trial is approximately of 550 000 euros. To reach this goal we need your help… If you want to support financially our project, please follow this link.
Noël PAIRAULT
Last 6th and 7th of October, three members of the team were at the « Photonic and Electronic Molecular Machines » (PEM2) symposium at Toulouse.